BEYAZ (Drospirenone; Ethinyl Estradiol; Levomefolate Calcium) Patent Expiration, LOE Window & CMS Spending

BEYAZ (Drospirenone; Ethinyl Estradiol; Levomefolate Calcium) by Bayer: FDA Orange Book core substance LOE 2030-07-17, 4 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN022532 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-07-17
Last Listed Patent or Exclusivity Date2030-07-17
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.